- Prostate cancer is a type of cancer that can be fatal.
- The exact treatment for prostate cancer depends on the person and the severity of the cancer.
- Researchers are still working to improve treatment options for prostate cancer.
- Recent studies have shown that the combination of three different treatments improves survival in men with prostate cancer.
Cancer affects people all over the world. Experts are constantly assessing how different treatments can eliminate or delay the spread of cancer.
Each type of cancer is different, leading to the development of various treatments and detection methods.
Recent studies displayed in Lancet We have found that certain combination therapies may improve the survival rate of men with prostate cancer.
Prostate cancer is one of the most common types of cancer among men.As pointed out by Centers for Disease Control and Prevention (CDC) In 2018, there were more than 210,000 new cases of prostate cancer, which killed nearly 31,500 prostate cancer patients.
As pointed out by American Cancer Society, Several different methods can help detect prostate cancer. One is to have a prostate-specific antigen (PSA) blood test.
If the PSA level is higher than a certain reference point, it may indicate prostate cancer. However, this is not a definitive diagnostic tool, as there are other reasons for higher PSA levels.
Doctors can also do a rectal exam to feel the prostate and notice any abnormal lumps. To confirm the elevated PSA or abnormal findings of a rectal exam, the doctor orders a prostate biopsy. Once this confirms the presence of prostate cancer, treatment can be started.
For prostate cancer, there are one or more options, including surgery, radiation therapy, cryotherapy, hormone therapy, immunotherapy, and chemotherapy. Researchers continue to work on improving treatment options and survival rates for patients with prostate cancer.
Research Lancet It was a randomized controlled trial. Researchers have divided men with prostate cancer into three different treatment groups.
This study included participants who had previously had a prostatectomy and showed specific PSA levels after prostatectomy. A total of 1,792 participants enrolled in the study.
Researchers have sought to find out if certain combination therapies improve survival and reduce the progression of severe cancer.
They used the label “Freedom from Progress”. The three treatment groups included three different treatment methods.
- Group 1 received a form of radiation called salvage prostate bed radiation therapy (PBRT). It specifically targets the prostate area after removal of the prostate.
- Group 2 received the same radiation as Group 1 (PBRT) and also received short-term Androgen deprivation therapy (ADT)Suppresses certain hormones and works to reduce fuel for cancerous prostate cells
- Group 3 received the same treatment as Group 2 with one additional component added. This group received PBRT, ADT, and pelvic lymph node radiation therapy (PLNRT). This is a type of radiation that explicitly targets the lymph nodes in the area of the pelvis where the prostate is located. The cancer may spread.
The study found that freedom from progression after 5 years was highest among people in Group 3. In Group 1, almost 71% of the groups had freedom from progress. In Group 3, that percentage was 87.4%.
These results indicate that the addition of short-term androgen ablation therapy and pelvic lymph node radiation therapy to rescue prostate bed radiation therapy can improve the survival rate of prostate cancer patients.
Research author Dr. Alan Pollack Note the following highlights Today’s medical news:
“This is the first randomized study to demonstrate the gradual benefits of adding pelvic lymph node treatment to androgen deprivation therapy and standard prostate bed treatment. This is the standard treatment prostate bed RT (PBRT), PBRT and short-term androgen deprivation therapy (STADT), and PBRT and STADT and pelvic lymph node therapy (PLNRT) are three groups of studies designed to test the enhancement of treatment. The primary endpoint is from progression. Was free for 5 years [and the study] Overall, it was shown that adding ADT gradually increased it, and adding PLNRT increased it further. “
The authors of the study note that using this combination therapy is not without risk. They point out that it can increase the risk of certain bone marrow problems. They also state that longer follow-up times are needed to confirm the full effectiveness of the treatment.
Dr. Kelvin Moses the director of the Vanderbilt University Medical Center’s Comprehensive Prostate Cancer Clinic, who was not involved in the study, agreed that further follow-up was needed, but said the results so far were promising.
He explained MNT that “[t]His work emphasizes the importance of controlling pelvic lymph nodes during surgery or in the context of recurrence after prostatectomy. “
He added:[i]Although it is not yet known whether the benefits of progression will lead to reduced metastasis or mortality from prostate cancer, these results are promising and may change the treatment paradigm for biochemical recurrence. ”
The authors of the study also note that as prostate imaging improves, it affects how this treatment is applied. However, this study provides overall promising results that can improve survival in prostate cancer patients who receive the appropriate type of treatment.
Dr. Haley Whitaker a cancer expert at the University of London, who was not involved in this study, was enthusiastic about the results.
“There are several ways to treat patients with prostate cancer, but using different treatments or combining different treatments is very likely to prolong it. [the] The life of a man for many years. “
According to her, “”[t]He is a groundbreaking study that could have a real impact on men being treated for prostate cancer by making significant advances in the combination of surgery, radiation therapy and hormone therapy. “